Abstract
Data from the phase III ENHANCE clinical trials provide compelling evidence that ensifentrine, an inhaled ‘bifunctional’ dual phosphodiesterase 3/4 inhibitor, can provide additional benefit to existing treatments in patients with chronic obstructive pulmonary disease and represents a ‘first-in-class’ drug having bifunctional bronchodilator and anti-inflammatory activity in a single molecule. Ensifentrine, generally well tolerated, can provide additional bronchodilation when added to muscarinic receptor antagonists or β2-agonists and reduce the exacerbation risk. This information allows us to consider better the possible inclusion of ensifentrine in the future treatment of chronic obstructive pulmonary disease. However, there is less information on whether it provides additional benefit when added to inhaled corticosteroid or ‘triple therapy’ and, therefore, when this drug is best utilized in clinical practice.
Plain language summary
Chronic obstructive pulmonary disease (COPD) is the name for a group of lung conditions that cause breathing difficulties/airflow limitations. The airflow limitation is not completely reversible and is associated with a state of chronic inflammation of lung tissue. Treatment of the disease is still heavily dependent on the use of medications called bronchodilators and corticosteroids. However, corticosteroids have little-to-no impact on the underlying inflammation in most COPD patients. Therefore, innovative anti-inflammatory approaches are required. In this context, single molecules that are capable of simultaneously inducing bronchodilation, relaxing the muscles in the lungs and widening the airways (bronchi), and anti-inflammatory activity are a highly intriguing possibility for treating COPD. One approach is to develop drugs that can simultaneously inhibit enzymes called phosphodiesterase (PDE)3 and PDE4. Enzymes are proteins that help speed up metabolism, or the chemical reactions in our bodies. PDE4 inhibitors are intracellular enzymes (work inside the cell) expressed in most inflammatory cells, even in neutrophils (a type of white blood cells), which are involved in the pathogenesis of COPD, where an infection turns into a disease. However, its inhibition does not produce severe bronchodilator effects, which is instead obtained by inhibiting PDE3, the PDE isoenzyme (a different form of the same enzyme) that is predominantly expressed in airway smooth muscle cells. A treatment called ensifentrine is a dual PDE3/4 inhibitor (inhibits both PDE3 and PDE4). Two recent phase III studies (ENHANCE-1 and ENHANCE-2) have shown that it induces significant bronchodilation and reduces the risk of COPD worsening, exerting an anti-inflammatory effect. Data from the ENHANCE studies also showed the benefit of adding ensifentrine to treatment with bronchodilators. Certainly, the drug represents a useful therapeutic option, but further clinical studies are needed to be able to correctly position ensifentrine in the context of regular COPD treatment.
Tweetable abstract
Ensifentrine, an inhaled ‘bifunctional’ dual PDE3/4 inhibitor, can provide additional benefit to existing treatments in patients with COPD and represents a ‘first in class’ drug having bifunctional bronchodilator and anti-inflammatory activity in a single molecule.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J. Pharmacol. Exp. Ther. 318(2), 840–848 (2006).
- 2. . An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD. Eur. Respir. J. 52(5), 1801675 (2018).
- 3. . Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol. 165(3), 152–164 (2014).
- 4. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitised human airways. Br. J. Pharmacol. 131(8), 1607–1618 (2000).
- 5. . Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin. Pharmacol. Toxicol. 114, 365–376 (2014). • Dual phosphodiesterase (PDE3)/4 and PDE4 inhibitors: novel treatments for chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.
- 6. A pathophysiological role of PDE3 in allergic airway inflammation. JCI Insight. 3(2), e94888 (2018).
- 7. . Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am. J. Respir. Cell Mol. Biol. 29(3 Pt 1), 410–418 (2003).
- 8. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J. Biol. Chem. 280(9), 7997–8003 (2005).
- 9. . Bifunctional drugs for the treatment of respiratory diseases. Handb. Exp. Pharmacol. 237, 197–212 (2017).
- 10. . Ensifentrine (RPL554): an inhaled ‘bifunctional’ dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharm. Pat. Anal. 7(6), 249–257 (2018).
- 11. . Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin. Investig. Drugs. 28(10), 827–833 (2019).
- 12. . Ensifentrine as a novel, inhaled treatment for patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 18, 1611–1622 (2023). • Nonclinical data, as well as phase I and II safety and efficacy outcomes of nebulized ensifentrine relevant to the maintenance therapy of COPD patients, are summarized in this article.
- 13. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J. Pharmacol. Exp. Ther. 346(3), 414–423 (2013).
- 14. . Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm. Pharmacol. Ther. 32, 15–23 (2015).
- 15. . Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility. Br. J. Pharmacol. 173(15), 2335–2351 (2016).
- 16. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir. Med. 1(9), 714–727 (2013).
- 17. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 310(1), L59–L70 (2016).
- 18. . Ensifentrine: A first-in-class bifunctional drug for the treatment of chronic obstructive pulmonary disease. etouchREVIEWS Respir. Pulmon. Dis. 7(2), 48–53 (2022). • Highlights the unanswered questions that emerged from analyzing phase I and II clinical development data concerning the possible positioning of ensifentrine in the COPD treatment scheme.
- 19. . Twice-daily, nebulized ensifentrine produced significant improvement in week 12 lung function: subgroup analysis in the phase 3 trial ENHANCE-2. Am. J. Respir. Crit. Care Med. 207, A2838 (2023).
- 20. . Ensifentrine reduced healthcare resource utilization in subjects with COPD: results from ENHANCE-2, a phase 3 trial of ensifentrine, a dual PDE3/4 inhibitor. Am. J. Respir. Crit. Care Med. 207, A2839 (2023).
- 21. . Treatment with ensifentrine, a dual PDE3 and PDE4 inhibitor, significantly reduced exacerbation rate and risk in subjects with COPD: sub-group results from the phase 3 trial, ENHANCE-2. Am. J. Respir. Crit. Care Med. 207, A4998 (2023).
- 22. . Ensifentrine, a dual inhibitor of PDE3 and PDE4, reduces the risk of exacerbation regardless of background medication use: a sub-group analysis of ENHANCE-2, a phase 3 trial. Am. J. Respir. Crit. Care Med. 207, A4999 (2023).
- 23. . Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, in moderate and severe COPD: symptoms, quality of life and health status from the phase 3 trial ENHANCE-2. Am. J. Respir. Crit. Care Med. 207, A5000 (2023).
- 24. . Safety results from dual PDE3/4 inhibitor ensifentrine: gastrointestinal and cardiovascular safety from a 24-week phase 3 trial, ENHANCE-2. Am. J. Respir. Crit. Care Med. 207, A5003 (2023).
- 25. . Twice-daily, nebulized ensifentrine significantly improves lung function: sub-group analysis in the phase 3 trial, ENHANCE-1. Am. J. Respir. Crit. Care Med. 207, A5004 (2023).
- 26. . Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in the ENHANCE-1 phase 3 trial of ensifentrine in COPD. Am. J. Respir. Crit. Care Med. 207, A5006 (2023).
- 27. . Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly improves COPD symptoms and quality of life in the phase 3 ENHANCE-1 trial. Am. J. Respir. Crit. Care Med. 207, A5007 (2023).
- 28. . Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly reduces annualized exacerbations and delays the time to first exacerbation in COPD: pooled sub-group analyses of ENHANCE-1 and ENHANCE-2 phase 3 trials. Am. J. Respir. Crit. Care Med. 207, A5008 (2023).
- 29. . Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in patients with COPD: results from replicate phase 3 trials. Am. J. Respir. Crit. Care Med. 207, A5005 (2023).
- 30. Ensifentrine, a novel PDE3 and PDE4 inhibitor for the treatment of COPD: randomized, double-blind, placebo-controlled, multicenter, phase III trials (the ENHANCE trials). Am. J. Respir. Crit. Care Med. 208(4), 406–416 (2023). •• Key article that, by reporting the results of the two ENHANCE program studies, helps to understand the real position of ensifentrine in treating COPD.
- 31. . Verona Pharma: Targeting the large COPD market (2023). https://seekingalpha.com/article/4625531-verona-pharma-targeting-the-large-copd-market?mailingid=32348864&messageid=must_reads&serial=32348864.3878154&utm_campaign=Must%2BReads%2Brecurring%2B2023-08-09&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads
- 32. . The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur. Respir. J. 52(5), 1801074 (2018).
- 33. . A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir. Res. 21(1), 47 (2020). •• Important 4-week phase IIb study that showed that ensifentrine monotherapy was effective and safe and supported the continuing development of this PDE3/4 inhibitor in COPD.
- 34. . Additional bronchodilation by ensifentrine, a dual PDE3/4 inhibitor, when combined with a LAMA/LABA in patients with moderate to severe COPD. Am. J. Respir. Crit. Care Med. 201, A4298 (2020).
- 35. Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. Eur. Respir. J. 61(4), 2300239 (2023).
- 36. . Novel anti-inflammatory approaches to COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 18, 1333–1352 (2023).
- 37. . Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? Expert Opin. Pharmacother. 23(8), 917–927 (2022).
- 38. . The impact of muscarinic receptor antagonists on airway inflammation: a systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 16, 257–279 (2021).
- 39. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 196(2), 139–149 (2017).
- 40. . Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am. J. Physiol. Lung Cell. Mol. Physiol. 305(8), L530–L541 (2013).
- 41. . CFTR: cystic fibrosis and beyond. Eur. Respir. J. 44(4), 1042–1054 (2014).
- 42. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 310(1), L59–L70 (2016).
- 43. . Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulm. Pharmacol. Ther. 58, 101814 (2019).
- 44. . Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis. Pharmacol. Ther. 224, 107826 (2021).